[
  {
    "ts": null,
    "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
    "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765302863,
      "headline": "BioNTech: Maintaining \"Strong Buy\" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart",
      "id": 137743809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2242604824/image_2242604824.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "BioNTech stock is a \"Strong Buy\", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=5783584119cffb601eb58492ea4e972340515254eace6399b29cbe2e717b3bc0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
    "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
    "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299000,
      "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
      "id": 137742558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
      "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50"
    }
  },
  {
    "ts": null,
    "headline": "​Sanofi (SNY) Completes the Acquisition of Vicebio",
    "summary": "​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus […]",
    "url": "https://finnhub.io/api/news?id=2fbf72b28ab00b4fc5c6d003b5536557100a971d4636cc5b2bbb40db82b6bdc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765298360,
      "headline": "​Sanofi (SNY) Completes the Acquisition of Vicebio",
      "id": 137742819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformative multi-pathogen vaccines for respiratory viral infections. ​Management noted that this strategic acquisition brings Vicebio’s early-stage vaccine candidate for respiratory syncytial virus […]",
      "url": "https://finnhub.io/api/news?id=2fbf72b28ab00b4fc5c6d003b5536557100a971d4636cc5b2bbb40db82b6bdc1"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
    "summary": "SAN FRANCISCO, December 09, 2025--Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
    "url": "https://finnhub.io/api/news?id=b6129d6735c58a77078dd62c2efd9c72ed4935f9c720feb30431a39288825fef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292400,
      "headline": "Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
      "id": 137742820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, December 09, 2025--Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers",
      "url": "https://finnhub.io/api/news?id=b6129d6735c58a77078dd62c2efd9c72ed4935f9c720feb30431a39288825fef"
    }
  }
]